The Cooper Companies, Inc. (COO)

FairStock Score: 47/100 — MIXED

Key Financials

Strengths

• Defensible recurring revenue model with contact lenses and women's health products
• Solid free cash flow generation of $367.1M demonstrates operational efficiency
• Conservative balance sheet with D/E of 0.33 and Altman Z-Score of 3.28
• 12.77% net profit margin in Q1 2026 shows pricing power and cost management
• Large addressable market in vision correction with 1.0B+ potential customers globally

Concerns

• Abysmal capital efficiency: ROE of 4.87% and ROCE of 3.64% destroy shareholder value
• Extreme valuation at 34.81 P/E and 56.04 EV/EBITDA with negative 201% margin of safety
• Negligible FCF yield of 1.1% suggests minimal cash return to shareholders
• No visible revenue or profit growth metrics provided—growth trajectory unclear

AI Analysis

The Cooper Companies presents a classic case of a good business trading at a poor price. Let me be direct: at $76.55 with a P/E of 34.81 and an EV/EBITDA of 56.04, we're paying a significant premium for what amounts to a low-return business. The Graham Number of $25.42 reveals a margin of safety of negative 201%—this stock is priced for perfection. What attracts me initially is the business itself. Cooper operates in two defensive segments: contact lenses and women's health. These are recurring revenue streams with genuine customer switching costs. The company generated $1.0 billion in revenue last quarter with a 12.77% net margin—respectable operational execution. Free cash flow of $367.1M demonstrates legitimate cash generation, though the 1.1% FCF yield is anemic relative to valuation. However, the returns are disappointing. An ROE of 4.87% and ROCE of 3.64% are well below our cost of capital. For a $15 billion market capitalization company, these returns suggest the business isn't creating value—it's merely returning cash. The EV/EBITDA multiple of 56x is egregious for a mature medical devices company with no growth visibility. The balance sheet is manageable with a D/E ratio of 0.33, and the Piotroski F-Score of 7/9 indicates reasonable financial quality. The Altman Z-Score of 3.28 suggests low bankruptcy risk. Yet financial soundness doesn't justify valuation extremes. I would observe this company with great interest if it traded closer to $30-35, where the margin of safety would be appropriate for the mediocre returns it generates. Until then, this is a wealth trap masquerading as a healthcare play.

Bull Case

Cooper operates in essential healthcare categories with demographic tailwinds from aging populations and rising myopia rates. If management executes operational improvements and expands margins, the current installed base of satisfied customers could generate superior returns at current scale.

Bear Case

At current valuations, any deceleration in market growth or pricing pressure would render the stock uninvestable. Mature markets and competitive intensity in contact lenses may constrain growth, while the capital structure returns suggest the business cannot justify even modest multiples.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer